

MEDIA RELEASE

Stemlife Earns AABB Accreditation for the Third Consecutive Time

- Stemlife has been accredited by AABB for the third time since its first accreditation in 2018
- AABB has been internationally recognised as the leading organisation for the development of blood banking, transfusion medicine, blood management and cellular therapy standards
- The accreditation is testament to the Group's dedication to establish itself as a leading healthcare solution provider and commitment to quality and safety

SINGAPORE, 25 April 2022 – Cordlife Group Limited (“**Cordlife**”, together with its subsidiaries, the “**Group**”), a Singapore Exchange mainboard listed company, is pleased to announce that its majority owned subsidiary, Stemlife Berhad (the “**Company**”), has been re-accredited by the AABB for the third consecutive time since its first in 2018.

Since its inception in 1957, AABB has been internationally recognised as the global leader in developing standards for blood banking, transfusion medicine, blood management and cellular therapies. AABB accreditation is the result of an intensive assessment by specially trained assessors who evaluate internal policies and procedures and determine whether the facility's level of medical, technical and administrative performance meets or exceeds the AABB standards. The evaluation covers every aspect of cord blood banking, including cord blood collection, transportation, receiving, processing, storage and release.

The Group has continued to demonstrate its dedication to safety and quality, and its facility in Singapore was the first private cord blood bank in Southeast Asia to be accredited by AABB in 2005. Besides the AABB accreditation, the Group's facilities throughout the region are also accredited by a number of other internationally recognised organisations, including FACT and CAP.

“We are pleased that Stemlife has been re-accredited by the AABB,” said Ms Tan Poh Lan, Group CEO and Executive Director of Cordlife Group Limited. We believe that voluntarily submitting to these rigorous assessments by leading international organisations distinguishes us and provides the assurance that our existing and prospective clients need to know about the services we provide. As we continue to progress and develop the use of stem cell therapy with clinicians, we will continue to provide high-quality service to ensure the safety of our clients and their families when they use their stored cord blood for treatment.”

End



ABOUT AABB

AABB (Association for the Advancement of Blood & Biotherapies) is an international, not-for-profit organization representing individuals and institutions involved in the fields of transfusion medicine and biotherapies. The Association works collaboratively to advance the field through the development and delivery of standards, accreditation and education programs. AABB is dedicated to its mission of improving lives by making transfusion medicine and biotherapies safe, available and effective worldwide. For more information, please visit www.aabb.org

ABOUT CORDLIFE GROUP LIMITED

Cordlife Group Limited (“Cordlife”, together with its subsidiaries, the “Group”), founded in 2001, is a leading company dedicated to safeguarding the well-being of mother and child. Listed on the Mainboard of the Singapore Exchange since 2012, the Group is a pioneer in private cord blood banking in Asia. Cordlife operates Asia’s largest network of cord blood banks. With full stem cell banking facilities in six key markets, Cordlife is an industry leader in Singapore, Hong Kong, Indonesia and the Philippines, and one of the top three market leaders in India and Malaysia. Through its majority-owned subsidiary in Malaysia, Stemlife Berhad, Cordlife has an indirect stake in Thailand’s largest private cord blood bank, Thai Stemlife. In addition to cord blood, cord lining and cord tissue banking, Cordlife offers families a comprehensive suite of diagnostics services, including non-invasive prenatal testing, paediatric vision screening and newborn metabolic screening. Two of Cordlife’s primary focus areas are providing reliable quality and being customer-centric. All of the Group’s facilities are accredited by the Association for the Advancement of Blood & Biotherapies (“AABB”), an organisation dedicated to its mission of improving lives by making transfusion medicine and biotherapies safe, available and effective worldwide. Furthermore, Cordlife Singapore and Healthbaby Hong Kong are the only two full-fledged private cord blood banks in Asia and five worldwide to be accredited by both AABB and the Foundation for the Accreditation of Cellular Therapy (“FACT”), another world-class accreditation body for cord blood banks worldwide. In the area of clinical diagnostics, Cordlife India, Cordlife Hong Kong and Healthbaby Hong Kong are all accredited by the College of American Pathologists (“CAP”). This makes Healthbaby Hong Kong the only private cord blood bank in the world to be accredited by three international standard-setting bodies, and Cordlife India one of the only two medical laboratories in West Bengal to be holding accreditations from the National Accreditation Board for Testing and Calibration Laboratories (“NABL”) and CAP. These quality achievements reinforce the Group’s commitment to providing reliable healthcare solutions through innovation and technological advancement. For more information, visit <http://cordlife.listedcompany.com>.

ISSUED ON BEHALF OF : Cordlife Group Limited

BY : Financial PR
4 Robinson Road #04-01
The House of Eden
Singapore 048543



CONTACT : Mr Maverick Lim
OFFICE : (65) 9272 1071
EMAIL : maverick@financialpr.com.sg